Anna Panasiuk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anna Panasiuk has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Igor Olejnik
Department of Pediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland
3 shared publications - Jowita Frączkiewicz
Department of Paediatric Haematology, Oncology and BMT, Wroclaw Medical University, 50-367 Wrocław, Poland
3 shared publications - Krzysztof Kałwak
Clinical Department of Pediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University, 213 Borowska St., 50-556 Wroclaw, Poland
3 shared publications - Tomasz Jarmoliński
Department of Pediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University, Wroclaw, Poland
3 shared publications - Blanka Rybka
Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, 50-556 Wroclaw, Poland
2 shared publications - Ewa Gorczyńska
Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, 50-556 Wroclaw, Poland
2 shared publications
Latest Publications
- Open Access
- 28 February 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (3) , 552
Between the Sponge and the Tap—Bacterial Communities at Overlooked Hospital Hygiene Hotspots
Hospital environments host diverse microbial communities that may contribute to nosocomial infections. Moisture-retaining surfaces such as cleaning sponges and faucet edges represent high-contact, under-investigated hygiene hotspots, particularly in wards caring for immunocompromised patients. Environmental samples were collected from cleaning sponges (n = 14) and faucet edges (n = 4) across multiple hospital rooms of a paediatric haematology–oncology unit, with domestic physician sponges as controls (n = 3). DNA was extracted and sequenced targeting the V3–V4 and V7–V9 hypervariable regions of the 16S rRNA gene on the Illumina MiSeq platform. Taxonomic composition and alpha/beta diversity were assessed using QIIME 2 and R. Sponge samples were dominated by Moraxellaceae, particularly Acinetobacter and Enhydrobacter, and showed significantly lower alpha diversity than faucet samples (Shannon index: Kruskal–Wallis H = 8.4, p = 0.01; Faith’s phylogenetic diversity: H = 9.17, p = 0.01). Faucet samples were enriched in human-associated genera including Staphylococcus, Streptococcus, and Chryseobacterium. Statistically significant beta-diversity differences were detected between sponge and faucet communities by PERMANOVA based on Bray–Curtis dissimilarity (p = 0.01), whereas no significant clustering by room or floor location was observed (p = 0.29). Potentially pathogenic taxa including Aeromonas, Pseudomonas, and Enterobacteriaceae were identified across both surface types. Domestic control sponges showed distinct microbiome profiles from hospital samples. Microbial communities differ significantly between hospital sponges and faucets, with surface type rather than location as the primary determinant of community structure. The presence of opportunistic pathogens on both surface types highlights the importance of enhanced hygiene protocols, inclusion of faucet edges and sink drains in routine decontamination schedules, and regular microbiological surveillance in clinical settings caring for immunocompromised patients.
- 28 February 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (3) , 552
Open AccessBetween the Sponge and the Tap—Bacterial Communities at Overlooked Hospital Hygiene Hotspots
Hospital environments host diverse microbial communities that may contribute to nosocomial infections. Moisture-retaining surfaces such as cleaning sponges and faucet edges represent high-contact, under-investigated hygiene hotspots, particularly in wards caring for immunocompromised patients. Environmental samples were collected from cleaning sponges (n = 14) and faucet edges (n = 4) across multiple hospital rooms of a paediatric haematology–oncology unit, with domestic physician sponges as controls (n = 3). DNA was extracted and sequenced targeting the V3–V4 and V7–V9 hypervariable regions of the 16S rRNA gene on the Illumina MiSeq platform. Taxonomic composition and alpha/beta diversity were assessed using QIIME 2 and R. Sponge samples were dominated by Moraxellaceae, particularly Acinetobacter and Enhydrobacter, and showed significantly lower alpha diversity than faucet samples (Shannon index: Kruskal–Wallis H = 8.4, p = 0.01; Faith’s phylogenetic diversity: H = 9.17, p = 0.01). Faucet samples were enriched in human-associated genera including Staphylococcus, Streptococcus, and Chryseobacterium. Statistically significant beta-diversity differences were detected between sponge and faucet communities by PERMANOVA based on Bray–Curtis dissimilarity (p = 0.01), whereas no significant clustering by room or floor location was observed (p = 0.29). Potentially pathogenic taxa including Aeromonas, Pseudomonas, and Enterobacteriaceae were identified across both surface types. Domestic control sponges showed distinct microbiome profiles from hospital samples. Microbial communities differ significantly between hospital sponges and faucets, with surface type rather than location as the primary determinant of community structure. The presence of opportunistic pathogens on both surface types highlights the importance of enhanced hygiene protocols, inclusion of faucet edges and sink drains in routine decontamination schedules, and regular microbiological surveillance in clinical settings caring for immunocompromised patients.
- Open Access
- 21 July 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (7) , 1622
The Kinetics of Inflammation-Related Proteins and Cytokines in Children Undergoing CAR-T Cell Therapy—Are They Biomarkers of Therapy-Related Toxicities?
CD19-targeted CAR-T cell therapy has revolutionized the treatment of relapsed/refractory (r/r) pre-B acute lymphoblastic leukemia (ALL). However, it can be associated with acute toxicities related to immune activation, particularly cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Cytokines released from activated immune cells play a key role in their pathophysiology. This study was a prospective analysis of proinflammatory proteins and cytokines in children treated with tisagenlecleucel. Serial measurements of C-reactive protein, fibrinogen, ferritin, IL-6, IL-8, IL-10, IFNγ, and TNFα were taken before treatment and on consecutive days after infusion. The incidence of CRS was 77.8%, and the incidence of ICANS was 11.1%. No CRS of grade ≥ 3 was observed. All complications occurred within 14 days following infusion. Higher biomarker concentrations were found in children with CRS grade ≥ 2. Their levels were correlated with disease burden and CAR-T cell dose. While cytokine release syndrome was common, most cases were mild, primarily due to low disease burden before lymphodepleting chemotherapy (LDC). ICANS occurred less frequently but exhibited various clinical courses. None of the toxicities were fatal. All of the analyzed biomarkers rose within 14 days after CAR-T infusion, with most reaching their maximum around the third day following the procedure.
- 21 July 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (7) , 1622
Open AccessThe Kinetics of Inflammation-Related Proteins and Cytokines in Children Undergoing CAR-T Cell Therapy—Are They Biomarkers of Therapy-Related Toxicities?
CD19-targeted CAR-T cell therapy has revolutionized the treatment of relapsed/refractory (r/r) pre-B acute lymphoblastic leukemia (ALL). However, it can be associated with acute toxicities related to immune activation, particularly cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Cytokines released from activated immune cells play a key role in their pathophysiology. This study was a prospective analysis of proinflammatory proteins and cytokines in children treated with tisagenlecleucel. Serial measurements of C-reactive protein, fibrinogen, ferritin, IL-6, IL-8, IL-10, IFNγ, and TNFα were taken before treatment and on consecutive days after infusion. The incidence of CRS was 77.8%, and the incidence of ICANS was 11.1%. No CRS of grade ≥ 3 was observed. All complications occurred within 14 days following infusion. Higher biomarker concentrations were found in children with CRS grade ≥ 2. Their levels were correlated with disease burden and CAR-T cell dose. While cytokine release syndrome was common, most cases were mild, primarily due to low disease burden before lymphodepleting chemotherapy (LDC). ICANS occurred less frequently but exhibited various clinical courses. None of the toxicities were fatal. All of the analyzed biomarkers rose within 14 days after CAR-T infusion, with most reaching their maximum around the third day following the procedure.
- Open Access
- 13 November 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (11) , 2915
Blinatumomab Prior to CAR-T Cell Therapy—A Treatment Option Worth Consideration for High Disease Burden
The optimal bridging therapy before CAR-T cell infusion in pediatric relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r BCP-ALL) still remains an open question. The administration of blinatumomab prior to CAR-T therapy is controversial since a potential loss of CD19+ target cells may negatively impact the activation, persistence, and, as a consequence, the efficacy of subsequently used CAR-T cells. Here, we report a single-center experience in seven children with chemorefractory BCP-ALL treated with blinatumomab before CAR-T cell therapy either to reduce disease burden before apheresis (six patients) or as a bridging therapy (two patients). All patients responded to blinatumomab except one. At the time of CAR-T cell infusion, all patients were in cytological complete remission (CR). Four patients had low positive PCR-MRD, and the remaining three were MRD-negative. All patients remained in CR at day +28 after CAR-T infusion, and six out of seven patients were MRD-negative. With a median follow-up of 497 days, four patients remain in CR and MRD-negative. Three children relapsed with CD19 negative disease: two of them died, and one, who previously did not respond to blinatumomab, was successfully rescued by stem cell transplant. To conclude, blinatumomab can effectively lower disease burden with fewer side effects than standard chemotherapeutics. Therefore, it may be a valid option for patients with high-disease burden prior to CAR-T cell therapy without clear evidence of compromising efficacy; however, further investigations are necessary.
- 13 November 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (11) , 2915
Open AccessBlinatumomab Prior to CAR-T Cell Therapy—A Treatment Option Worth Consideration for High Disease Burden
The optimal bridging therapy before CAR-T cell infusion in pediatric relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r BCP-ALL) still remains an open question. The administration of blinatumomab prior to CAR-T therapy is controversial since a potential loss of CD19+ target cells may negatively impact the activation, persistence, and, as a consequence, the efficacy of subsequently used CAR-T cells. Here, we report a single-center experience in seven children with chemorefractory BCP-ALL treated with blinatumomab before CAR-T cell therapy either to reduce disease burden before apheresis (six patients) or as a bridging therapy (two patients). All patients responded to blinatumomab except one. At the time of CAR-T cell infusion, all patients were in cytological complete remission (CR). Four patients had low positive PCR-MRD, and the remaining three were MRD-negative. All patients remained in CR at day +28 after CAR-T infusion, and six out of seven patients were MRD-negative. With a median follow-up of 497 days, four patients remain in CR and MRD-negative. Three children relapsed with CD19 negative disease: two of them died, and one, who previously did not respond to blinatumomab, was successfully rescued by stem cell transplant. To conclude, blinatumomab can effectively lower disease burden with fewer side effects than standard chemotherapeutics. Therefore, it may be a valid option for patients with high-disease burden prior to CAR-T cell therapy without clear evidence of compromising efficacy; however, further investigations are necessary.
- Open Access
- 15 August 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (8) , 5748-5762
The Use of Assisted Reproductive Technology by European Childhood Cancer Survivors
CCS often wish to have biological children yet harbour concerns about fertility impairment, pregnancy risks and the general health risks of prospective offspring. To clarify these concerns, health outcomes in survivor offspring born following ART (n = 74, 4.5%) or after spontaneous conception (n = 1585) were assessed in our European offspring study by descriptive and bivariate analysis. Outcomes were compared to a sibling offspring cohort (n = 387) in a 4:1 matched-pair analysis (n = 1681). (i) Survivors were more likely to employ ART than their siblings (4.5% vs. 3.7%, p = 0.501). Successful pregnancies were achieved after a median of one cycle with, most commonly, intracytoplasmic sperm injection (ICSI) using non-cryopreserved oocytes/sperm. (ii) Multiple-sibling births (p < 0.001, 29.7% vs. 2.5%), low birth weight (p < 0.001; OR = 3.035, 95%-CI = 1.615–5.706), and preterm birth (p < 0.001; OR = 2.499, 95%-CI = 1.401–4.459) occurred significantly more often in survivor offspring following ART utilisation than in spontaneously conceived children. ART did not increase the prevalence of childhood cancer, congenital malformations or heart defects. (iii) These outcomes had similar prevalences in the sibling population. In our explorative study, we could not detect an influence on health outcomes when known confounders, such as multiple births, were taken into account.
- 15 August 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (8) , 5748-5762
Open AccessThe Use of Assisted Reproductive Technology by European Childhood Cancer Survivors
CCS often wish to have biological children yet harbour concerns about fertility impairment, pregnancy risks and the general health risks of prospective offspring. To clarify these concerns, health outcomes in survivor offspring born following ART (n = 74, 4.5%) or after spontaneous conception (n = 1585) were assessed in our European offspring study by descriptive and bivariate analysis. Outcomes were compared to a sibling offspring cohort (n = 387) in a 4:1 matched-pair analysis (n = 1681). (i) Survivors were more likely to employ ART than their siblings (4.5% vs. 3.7%, p = 0.501). Successful pregnancies were achieved after a median of one cycle with, most commonly, intracytoplasmic sperm injection (ICSI) using non-cryopreserved oocytes/sperm. (ii) Multiple-sibling births (p < 0.001, 29.7% vs. 2.5%), low birth weight (p < 0.001; OR = 3.035, 95%-CI = 1.615–5.706), and preterm birth (p < 0.001; OR = 2.499, 95%-CI = 1.401–4.459) occurred significantly more often in survivor offspring following ART utilisation than in spontaneously conceived children. ART did not increase the prevalence of childhood cancer, congenital malformations or heart defects. (iii) These outcomes had similar prevalences in the sibling population. In our explorative study, we could not detect an influence on health outcomes when known confounders, such as multiple births, were taken into account.
- 1 December 2021
- Published by Elsevier in Cancer Epidemiology
- Vol. 75, 102052
Health of children born to childhood cancer survivors: Participant characteristics and methods of the Multicenter Offspring Study
- 1 December 2021
- Published by Elsevier in Cancer Epidemiology
- Vol. 75, 102052
Health of children born to childhood cancer survivors: Participant characteristics and methods of the Multicenter Offspring Study
- Open Access
- 26 September 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (19) , 4416
Fludarabine–Cyclophosphamide-Based Conditioning with Antithymocyte Globulin Serotherapy Is Associated with Durable Engraftment and Manageable Infections in Children with Severe Aplastic Anemia
Severe aplastic anemia (SAA) is a bone marrow failure syndrome that can be treated with hematopoietic cell transplantation (HCT) or immunosuppressive (IS) therapy. A retrospective cohort of 56 children with SAA undergoing transplantation with fludarabine–cyclophosphamide–ATG-based conditioning (FluCyATG) was analyzed. The endpoints were overall survival (OS), event-free survival (EFS), cumulative incidence (CI) of graft versus host disease (GVHD) and CI of viral replication. Engraftment was achieved in 53/56 patients, and four patients died (two due to fungal infection, and two of neuroinfection). The median time to neutrophil engraftment was 14 days and to platelet engraftment was 16 days, and median donor chimerism was above 98%. The overall incidence of acute GVHD was 41.5%, and that of grade III-IV acute GVHD was 14.3%. Chronic GVHD was diagnosed in 14.2% of children. The probability of 2-year GVHD-free survival was 76.1%. In the univariate analysis, a higher dose of cyclophosphamide and previous IS therapy were significant risk factors for worse overall survival. Episodes of viral replication occurred in 33/56 (58.9%) patients, but did not influence OS. The main advantages of FluCyATG include early engraftment with a very high level of donor chimerism, high overall survival and a low risk of viral replication after HCT.
- 26 September 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (19) , 4416
Open AccessFludarabine–Cyclophosphamide-Based Conditioning with Antithymocyte Globulin Serotherapy Is Associated with Durable Engraftment and Manageable Infections in Children with Severe Aplastic Anemia
Severe aplastic anemia (SAA) is a bone marrow failure syndrome that can be treated with hematopoietic cell transplantation (HCT) or immunosuppressive (IS) therapy. A retrospective cohort of 56 children with SAA undergoing transplantation with fludarabine–cyclophosphamide–ATG-based conditioning (FluCyATG) was analyzed. The endpoints were overall survival (OS), event-free survival (EFS), cumulative incidence (CI) of graft versus host disease (GVHD) and CI of viral replication. Engraftment was achieved in 53/56 patients, and four patients died (two due to fungal infection, and two of neuroinfection). The median time to neutrophil engraftment was 14 days and to platelet engraftment was 16 days, and median donor chimerism was above 98%. The overall incidence of acute GVHD was 41.5%, and that of grade III-IV acute GVHD was 14.3%. Chronic GVHD was diagnosed in 14.2% of children. The probability of 2-year GVHD-free survival was 76.1%. In the univariate analysis, a higher dose of cyclophosphamide and previous IS therapy were significant risk factors for worse overall survival. Episodes of viral replication occurred in 33/56 (58.9%) patients, but did not influence OS. The main advantages of FluCyATG include early engraftment with a very high level of donor chimerism, high overall survival and a low risk of viral replication after HCT.
- 26 February 2021
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 16 (1) , 1-11
A long-term trajectory of bone mineral density in childhood cancer survivors after discontinuation of treatment: retrospective cohort study
Summary Low bone mineral density (BMD) was diagnosed in 24% of childhood cancer survivors (CCS), whereas very low BMD was relatively uncommon at 8%. We suggest that low BMD in CCS may become alleviated over time. Stem cell transplantation, radiotherapy, and underweight were the strongest independent predictors of decreased BMD. Purpose Childhood cancer survivors (CCS) are at risk of premature bone loss, although published studies are inconsistent. The objective of this study was to evaluate the prevalence and pattern of low bone mineral density (BMD) in short- and long-term CCS, and to determine clinical factors affecting skeleton after anticancer treatment. Methods This retrospective study was conducted in a cohort of 326 children and young adult CCS (147 females) who completed anticancer treatment. BMD was determined by dual-energy X-ray absorptiometry (DXA). Low BMD was defined as a Z-score ≤ − 1.0, and the very low BMD as a Z-score ≤ − 2.0. Additionally, the changes in BMD over time were studied in 123 CCS who had been re-examined by DXA during follow-up. Results Median age at diagnosis was 7.27 years (range, 4.4–10.6); median time between end of treatment and DXA was 6.12 (range, 4.0–22.0). Low BMD was found in 24% of CCS, while very low BMD was relatively uncommon (8%). Based on multivariate analysis, the following were significantly associated with low BMD at the follow-up: hematopoietic stem cell transplantation (OR 3.13, 95% CI 1.02–9.63), head and neck radiotherapy (OR 2.54, 95% CI 1.32–4.90), and body weight below the standard reference (OR 3.57, 95% CI 1.24–10.23). The time-related trajectory showed an improvement (BMDLS) or stabilization (BMDTB) in Z-scores values. Conclusion These data based on serial DXA measurements, encompassing a long-lasting observation period, show that CCS may not be at risk of premature bone loss in young adulthood. However, it is unknown how the scenario for skeletal mass is until the CCS will achieve older or postmenopausal age.
- 26 February 2021
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 16 (1) , 1-11
A long-term trajectory of bone mineral density in childhood cancer survivors after discontinuation of treatment: retrospective cohort study
Summary Low bone mineral density (BMD) was diagnosed in 24% of childhood cancer survivors (CCS), whereas very low BMD was relatively uncommon at 8%. We suggest that low BMD in CCS may become alleviated over time. Stem cell transplantation, radiotherapy, and underweight were the strongest independent predictors of decreased BMD. Purpose Childhood cancer survivors (CCS) are at risk of premature bone loss, although published studies are inconsistent. The objective of this study was to evaluate the prevalence and pattern of low bone mineral density (BMD) in short- and long-term CCS, and to determine clinical factors affecting skeleton after anticancer treatment. Methods This retrospective study was conducted in a cohort of 326 children and young adult CCS (147 females) who completed anticancer treatment. BMD was determined by dual-energy X-ray absorptiometry (DXA). Low BMD was defined as a Z-score ≤ − 1.0, and the very low BMD as a Z-score ≤ − 2.0. Additionally, the changes in BMD over time were studied in 123 CCS who had been re-examined by DXA during follow-up. Results Median age at diagnosis was 7.27 years (range, 4.4–10.6); median time between end of treatment and DXA was 6.12 (range, 4.0–22.0). Low BMD was found in 24% of CCS, while very low BMD was relatively uncommon (8%). Based on multivariate analysis, the following were significantly associated with low BMD at the follow-up: hematopoietic stem cell transplantation (OR 3.13, 95% CI 1.02–9.63), head and neck radiotherapy (OR 2.54, 95% CI 1.32–4.90), and body weight below the standard reference (OR 3.57, 95% CI 1.24–10.23). The time-related trajectory showed an improvement (BMDLS) or stabilization (BMDTB) in Z-scores values. Conclusion These data based on serial DXA measurements, encompassing a long-lasting observation period, show that CCS may not be at risk of premature bone loss in young adulthood. However, it is unknown how the scenario for skeletal mass is until the CCS will achieve older or postmenopausal age.
- 1 June 2013
- Published by Bioscientifica in Bone Abstracts
Time to low bone mass occurrence in children diagnosed with acute lymphoblastic leukemia
Objective: Assessment of low bone mass in children with acute lymphoblastic leukemia. Methods: A total of 141 patients (83 boys and 57 girls) treated for acute lymphoblastic leukemia at the Department of Pediatric Hematology and Oncology of Medical University of Bialystok in Poland were assessed for low bone mineral density. Depending on age of diagnosis three clinical groups were analyzed: i) up to 5 years old, ii) from 6 to 12 years old, and iii) from 13 to 18 years old. Survival was measured as the date of birth to the date of low bone mass at DXA scans or most recent follow-up. Statistical analysis was performed using Kaplan–Meier Method, Wilcoxon’s test and χ2 test. A P value P=0.218). However, the number of observed events of low bone mass in boys was lower than expected. Patients diagnosed between 6 and 12 years of age tended to have bone deficits earlier then patients diagnosed before 5 and after 13 year of life (P=0.068). Among all patients a low bone mass (defined as a Z-score ≤−2) was observed in a total of 17/83 boys and 20/57 girls (P=0.054). Conclusion: This study suggests that there is no difference in time of occurrence of low bone mass between the analyzed groups. However 20.5% of boys and 35% of girls had a low bone mass during the study. It seems that children diagnosed with acute lymphoblastic leukemia should be screened for bone mass.
- 1 June 2013
- Published by Bioscientifica in Bone Abstracts
Time to low bone mass occurrence in children diagnosed with acute lymphoblastic leukemia
Objective: Assessment of low bone mass in children with acute lymphoblastic leukemia. Methods: A total of 141 patients (83 boys and 57 girls) treated for acute lymphoblastic leukemia at the Department of Pediatric Hematology and Oncology of Medical University of Bialystok in Poland were assessed for low bone mineral density. Depending on age of diagnosis three clinical groups were analyzed: i) up to 5 years old, ii) from 6 to 12 years old, and iii) from 13 to 18 years old. Survival was measured as the date of birth to the date of low bone mass at DXA scans or most recent follow-up. Statistical analysis was performed using Kaplan–Meier Method, Wilcoxon’s test and χ2 test. A P value P=0.218). However, the number of observed events of low bone mass in boys was lower than expected. Patients diagnosed between 6 and 12 years of age tended to have bone deficits earlier then patients diagnosed before 5 and after 13 year of life (P=0.068). Among all patients a low bone mass (defined as a Z-score ≤−2) was observed in a total of 17/83 boys and 20/57 girls (P=0.054). Conclusion: This study suggests that there is no difference in time of occurrence of low bone mass between the analyzed groups. However 20.5% of boys and 35% of girls had a low bone mass during the study. It seems that children diagnosed with acute lymphoblastic leukemia should be screened for bone mass.
- 1 August 2008
- Vol. 25 (146) , 137-40
[Puvll and Xbal gene polymorphisms of estrogen receptor alpha in children and young adults with cancer from north-eastern region of Poland].
Polygene of the pathogenesis of osteoporosis and the number of factors influencing structure and functions of bone tissue challenge researches to further studies. Estrogen receptor alpha (ERalpha) gene polimorphism influences the transduction of the signal to the bone cells. The study aimed to establish the frequency of occurrence of Pvull and Xbal gene polymorphism of estrogen receptor alpha in a group of children and adolescents from north-eastern Poland with diagnosed and treated cancer. In the study of gene polymorphism a group of 205 children (113 boys) treated in Department of Pediatric Oncology and its' Outpatient Department in Bialystok was compared with a control group of 70 healthy children (38 boys) from the same part of Poland. Gene polymorphism was established using polymerase chain reaction (PCR) and Pvull and Xbal enzymes. In both groups heterozygots were prevalent (Pp - 49.27% and 51.43% Xx - 53.17% and 48.57%). The most often occurring genotype was px, and the rarest was pX genotype (1.46% in the study group). The influence of ERalpha polymorphism should be taken into account among the negative factors influencing the development of osteoporosis, especially in the case of prolonged lack or minimal physical activity.
- 1 August 2008
- Vol. 25 (146) , 137-40
[Puvll and Xbal gene polymorphisms of estrogen receptor alpha in children and young adults with cancer from north-eastern region of Poland].
Polygene of the pathogenesis of osteoporosis and the number of factors influencing structure and functions of bone tissue challenge researches to further studies. Estrogen receptor alpha (ERalpha) gene polimorphism influences the transduction of the signal to the bone cells. The study aimed to establish the frequency of occurrence of Pvull and Xbal gene polymorphism of estrogen receptor alpha in a group of children and adolescents from north-eastern Poland with diagnosed and treated cancer. In the study of gene polymorphism a group of 205 children (113 boys) treated in Department of Pediatric Oncology and its' Outpatient Department in Bialystok was compared with a control group of 70 healthy children (38 boys) from the same part of Poland. Gene polymorphism was established using polymerase chain reaction (PCR) and Pvull and Xbal enzymes. In both groups heterozygots were prevalent (Pp - 49.27% and 51.43% Xx - 53.17% and 48.57%). The most often occurring genotype was px, and the rarest was pX genotype (1.46% in the study group). The influence of ERalpha polymorphism should be taken into account among the negative factors influencing the development of osteoporosis, especially in the case of prolonged lack or minimal physical activity.